$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...

May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for the fina ...

Vesnaandjic/E+ via Getty Images Argenx Performance and Prospects Amid Market Challenges Argenx's (NASDAQ:ARGX) stock is down 22% since my last evaluation in October. Back then, I noted growing revenue opportunities for the company's lead asset, Vyvgart. argenx, a biotechnology developer based in Amsterdam, is a leader in the anti-FcRn market, which is expected to grow to over $10 billion. Last quarter (Q4), argenx reported $374 million in global net product revenues (Vyvgart and Vyvgart Hytrulo) and $41 ...

May 7, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors ...

May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in a fireside chat at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 10:00 AM PT in Las Vegas, NV. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A ...

May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A ...

May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A ...

GSK plc. (GSK) will report first-quarter 2024 results on May 1, before the opening bell. In the last reported quarter, the company reported a negative earnings surprise of 5.26%.Factors to NoteGSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines. Our model estimate for the company’s total revenues is pegged at £7.36 billion ($9.12 billion).In the first quarter, higher sales of newer products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingr ...

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE trial eval ...

Shares of Argenx (ARGX) rose 11.2% on Mar 21, after Japan-based Chugai Pharmaceutical posted disappointing results from a late-stage study evaluating Enspryng (satralizumab) as a potential treatment for generalized myasthenia gravis (gMG). This drug has been developed in collaboration with Roche (RHHBY) .The Tokyo-based company evaluated the Roche-partnered drug in the phase III LUMINESCE study in patients with gMG, a rare autoimmune disease that leads to muscle weakness. While patients who received the Chu ...